Related Experiment Video
Updated: May 22, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Statins impair glucose uptake in tumor cells
Agata Malenda1, Anna Skrobanska, Tadeusz Issat
1Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Neoplasia (New York, N.Y.)
|May 12, 2012
Summary
Statins significantly reduce glucose uptake in tumor cells by affecting glucose transporter 1 (GLUT1) function, not expression. This finding impacts cancer diagnostics like positron emission tomography (PET) scans.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Statins are lipid-lowering drugs impacting cardiovascular health.
- Statins modulate membrane cholesterol, influencing protein conformation, such as CD20.
- The effect of statins on glucose metabolism in cancer cells is not well understood.
Purpose of the Study:
- To investigate the impact of statins on glucose transporter 1 (GLUT1)-mediated glucose uptake in tumor cells.
- To explore the clinical relevance of statins' effects on glucose uptake.
Main Methods:
- In vitro studies using tumor cell lines to measure glucose analog uptake with statin treatment.
- Reversibility assays using mevalonic acid and exogenous cholesterol.
- Analysis of GLUT1 expression at transcriptional and protein levels.
- Exploratory clinical trial in a mantle cell lymphoma patient.
- Bioinformatics analysis of GLUT1 structure and cholesterol-binding motifs.
Main Results:
- Statins caused a concentration- and time-dependent decrease in glucose uptake in tumor cells.
- The effect was reversible upon restoring cholesterol synthesis or adding exogenous cholesterol.
- Statins did not alter GLUT1 expression levels.
- Clinical data showed reduced leukocyte and tumor (18)F-FDG uptake in a patient on statins.
- Bioinformatics identified potential cholesterol-binding sites in GLUT1.
Conclusions:
- Statins inhibit GLUT1-mediated glucose uptake in tumor cells through a mechanism independent of GLUT1 expression, likely involving cholesterol modulation.
- Statin-induced reduction in (18)F-FDG uptake may compromise the sensitivity of PET scans used in oncology.
- Further research is warranted to understand the clinical implications of statins on cancer imaging and metabolism.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...